

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

18-998/S-046

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	X
Final Printed Labeling	X
Medical Review(s)	
Chemistry Review(s)	
EA/FONSI	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative Document(s)	X
Correspondence	
Bioresearch Monitoring	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER(S)

NDA 18-998/S-046

Trade Name: Vasotec

Generic Name(s): (enalaprilat)

Sponsor: Merck Research Laboratories

Agent:

Approval Date: September 28, 1995

Indication: The treatment of hypertension.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-046

Approval Letter(s)



Food and Drug Administration
Rockville MD 20857

JUN 19 1995

NDA 18-998/S-046
19-221/S-021
19-309/S-019
19-558/S-031
19-778/S-025

Merck Research Laboratories
Attention: Larry P. Bell, M.D.
Sumneytown Pike
West Point, PA 19486

Dear Dr. Bell:

Please refer to your May 10, 1995 supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vasotec (enalapril) Tablets (NDA 18-998), Vaseretic (enalapril/hydrochlorothiazide) Tablets (NDA 19-221), Vasotec (enalaprilat) Intravenous (NDA 19-309), Prinivil (lisinopril) Tablets (NDA 19-558) and Prinzide (lisinopril/hydrochlorothiazide) Tablets (NDA 19-778).

The supplemental applications, submitted in response to our January 27, 1995 letter, provide for draft labeling revised by adding information stating that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks, and that they cause a higher rate of angioedema in black than in non-black patients.

We have completed the review of these supplemental applications as submitted with draft labeling and they are approvable. Before these supplements may be approved, however, it will be necessary for you to submit revised final printed labeling (FPL) as follows:

Our January 27, 1995 letter asked you to add the following statement at the end of the **INDICATIONS AND USAGE** section:

In considering use of [Tradename], it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

_____ deleted from the first sentence of the **ADVERSE REACTIONS, Angioedema** subsection for Vasotec _____, Vaseretic _____ and Prinivil _____ It was not included in the other applications.

It is not clear why the sentences "In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks." and _____

_____ under **INDICATIONS AND USAGE** specify ACE inhibitor monotherapy, since angioedema was seen in patients on ACE inhibitor/HCTZ combination products. Therefore, please delete the word "monotherapy" from these sentences at the time of your next printing and add an "s" to "ACE inhibitor;" the sentences would then read "In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks." and _____

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drugs are safe and effective for use as recommended in the final printed labeling included in the August 24, 1995 submission. Accordingly, the supplemental application are approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Ms. Kathleen Bongiovanni
Regulatory Health Project Manager
(301) 594-5334

Sincerely yours,

RJL 9/28/95

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

Original NDA

HF-2/MedWatch (with labeling)

HFD-80 (with labeling)

HFD-110

HFD-110/CSO

HFD-240 (with labeling)

HFD-613 (with labeling)

HFD-735/DBarash (with labeling)

HFD-110/KBongiovanni

sb/9/14/95;9/27/95

R/D: SChen/9/15/95

GBuehler for NMorgenstern/9/21/95

Approval Dates: 18-998 - 12/24/85
19-221 - 10/31/86
19-309 - 2/9/88
19-558 - 12/29/87
19-778 - 2/16/89

APPROVAL

KBongiovanni
9-27-95

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-046

Approvable Letter (s)



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 18-998/S-046
19-221/S-021
19-309/S-019
• 19-558/S-031
19-778/S-025

Merck Research Laboratories
Attention: Larry P. Bell, M.D.
Sumneytown Pike
West Point, PA 19486

Dear Dr. Bell:

Please refer to your May 10, 1995 supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vasotec (enalapril) Tablets (NDA 18-998), Vaseretic (enalapril/hydrochlorothiazide) Tablets (NDA 19-221), Vasotec (enalaprilat) Intravenous (NDA 19-309), Prinivil (lisinopril) Tablets (NDA 19-558) and Prinzide (lisinopril/hydrochlorothiazide) Tablets (NDA 19-778).

The supplemental applications, submitted in response to our January 27, 1995 letter, provide for draft labeling revised by adding information stating that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks, and that they cause a higher rate of angioedema in black than in non-black patients.

We have completed the review of these supplemental applications as submitted with draft labeling and they are approvable. Before these supplements may be approved, however, it will be necessary for you to submit revised final printed labeling (FPL) as follows:

Our January 27, 1995 letter asked you to add the following statement at the end of the **INDICATIONS AND USAGE** section:

In considering use of [Tradename], it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. _____

You have responded to our letter, however, by proposing that instead of revising the **INDICATIONS AND USAGE** section as requested, you would revise the labeling under **WARNINGS** and **ADVERSE REACTIONS** as follows:

Under the single entity products (Vasotec, Vasotec I.V. and Prinivil), addition of the following paragraph to the **WARNINGS** section:

Addition of a heading for the next paragraph, "Patients with a history of angioedema," addition of a dependent clause in the angioedema section of the **ADVERSE REACTIONS** section stating that angioedema has a higher incidence in black than in non-black patients, and addition of the word _____

Under the combination products (Vaseretic and Prinzide), you proposed adding the following paragraph to the **WARNINGS** section:

The additional revisions proposed above were also proposed for the combination labeling.

We have reviewed your proposal, and have decided that to maintain consistency in class labeling, the revisions should be made as we have originally requested. We have no objection to your reversing the order of the sentences in the statement used for the single entity products. The statements that you proposed for addition to the **WARNINGS** section may be used; they must, however, be placed in the **INDICATIONS AND USAGE** section.

The addition of the heading, _____ is acceptable. The addition of the clause in the **ADVERSE REACTIONS** section stating that angioedema has a higher incidence in black than in non-black patients is also acceptable, but because this is a restatement of what will be stated under **INDICATIONS AND USAGE**, is not needed.

The addition of the word _____ to describe the incidence of angioedema, under **WARNINGS** and **ADVERSE REACTIONS** in the Vasotec, Vaseretic, Vasotec I.V. and Prinivil labeling, however, is **NOT** acceptable. Also, please remove the word _____ from these sections in the Prinivil labeling. This was apparently a carry over from the original approval of this application and there are no data to indicate that the incidence of angioedema is _____ for Prinivil than it is for any other ACE inhibitor.

If additional information relating to the safety or effectiveness of these drugs becomes available, revision of the FPL may be required. Please submit fifteen copies of the printed labeling to each application ten of which are individually mounted on heavy weight paper or similar material.

Within 10 days after the date of this letter, you are required to amend these supplemental applications, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action, FDA may take action to withdraw these supplemental applications.

These changes may not be implemented until you have been notified in writing that these supplemental applications are approved.

Should you have any questions, please contact:

Ms. Kathleen Bongiovanni
Regulatory Health Project Manager
Telephone: (301) 594-5300

Sincerely yours,

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

Original NDA

HFC-130/JAllen

HFD-80

HFD-110

HFD-110/CSO

HFD-110/GBuehler;6/5/95

sb/6/5/95;6/8/95;6/8/95

R/D: CGanley/6/5/95

SChen/6/5/95

JShort/6/5/95

SZimmerman/6/6/95

RWolters/6/7/95

CResnick/6/7/95

NMorgenstern/6/7/95;6/8/95

Approval Dates: 18-998 - 12/24/85
19-221 - 10/31/86
19-309 - 2/9/88
19-558 - 12/29/87
19-778 - 2/16/89

APPROVABLE



NDA 18-998/S-046
19-221/S-021
19-309/S-019
~~19-558/S-031~~
19-778/S-025

Food and Drug Administration
Rockville MD 20857

SEP 28 1995

Merck Research Laboratories
Attention: Larry P. Bell, M.D.
Sumneytown Pike
West Point, PA 19486

Dear Dr. Bell:

Please refer to your May 10, 1995 supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vasotec (enalapril) Tablets (NDA 18-998), Vaseretic (enalapril/hydrochlorothiazide) Tablets (NDA 19-221), Vasotec (enalaprilat) Intravenous (NDA 19-309), Prinivil (lisinopril) Tablets (NDA 19-558) and Prinzide (lisinopril/hydrochlorothiazide) Tablets (NDA 19-778).

We acknowledge receipt of your amendment dated August 24, 1995.

The supplemental applications, submitted in response to our January 27, 1995 letter, provide for final printed labeling revised as follows:

INDICATIONS AND USAGE:

NDA 18-998, 19-309, 19-558

In considering use of Vasotec/Vasotec I.V./Prinivil, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. (See **WARNINGS, Angioedema.**)

NDA 19-221 and 19-778

In considering use of Vaseretic/Prinzide,

(See **WARNINGS, Angioedema.**)

WARNINGS, Anaphylactoid and Possibly Related Reactions, Angioedema: a reference to the _____ section has been added.

ADVERSE REACTIONS, Angioedema: The phrase "with an incidence higher in black than in non-black patients" has been added to the first sentence of this subsection. The word _____ was deleted from this sentence in the Prinzide labeling.

You have responded to our letter, however, by proposing that instead of revising the **INDICATIONS AND USAGE** section as requested, you would revise the labeling under **WARNINGS** and **ADVERSE REACTIONS** as follows:

Under the single entity products (Vasotec, Vasotec I.V. and Prinivil), addition of the following paragraph to the **WARNINGS** section:

Addition of a heading for the next paragraph, "Patients with a history of angioedema," addition of a dependent clause in the angioedema section of the **ADVERSE REACTIONS** section stating that angioedema has a higher incidence in black than in non-black patients, and addition of the word _____

Under the combination products (Vaseretic and Prinzide), you proposed adding the following paragraph to the **WARNINGS** section:

The additional revisions proposed above were also proposed for the combination labeling.

We have reviewed your proposal, and have decided that to maintain consistency in class labeling, the revisions should be made as we have originally requested. We have no objection to your reversing the order of the sentences in the statement used for the single entity products. The statements that you proposed for addition to the **WARNINGS** section may be used; they must, however, be placed in the **INDICATIONS AND USAGE** section.

The addition of the heading, _____ is acceptable. The addition of the clause in the **ADVERSE REACTIONS** section stating that angioedema has a higher incidence in black than in non-black patients is also acceptable, but because this is a restatement of what will be stated under **INDICATIONS AND USAGE**, is not needed.

The addition of the word _____ to describe the incidence of angioedema, under **WARNINGS** and **ADVERSE REACTIONS** in the Vasotec, Vasoretic, Vasotec I.V. and Prinivil labeling, however, is **NOT** acceptable. Also, please remove the word _____ from these sections in the Prinzide labeling. This was apparently a carry over from the original approval of this application and there are no data to indicate that the incidence of angioedema is _____ for Prinzide than it is for any other ACE inhibitor.

If additional information relating to the safety or effectiveness of these drugs becomes available, revision of the FPL may be required. Please submit fifteen copies of the printed labeling to each application ten of which are individually mounted on heavy weight paper or similar material.

Within 10 days after the date of this letter, you are required to amend these supplemental applications, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action, FDA may take action to withdraw these supplemental applications.

These changes may not be implemented until you have been notified in writing that these supplemental applications are approved.

Should you have any questions, please contact:

Ms. Kathleen Bongiovanni
Regulatory Health Project Manager
Telephone: (301) 594-5300

Sincerely yours,

RJ 6/19/95

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

Original NDA

HFC-130/JAllen

HFD-80

HFD-110

HFD-110/CSO

HFD-110/GBuehler;6/5/95

sb/6/5/95;6/8/95;6/8/95

R/D: CGanley/6/5/95

SChen/6/5/95

JShort/6/5/95

SZimmerman/6/6/95

RWolters/6/7/95

CResnick/6/7/95

NMorgenstern/6/7/95;6/8/95

Approval Dates: 18-998 - 12/24/85
19-221 - 10/31/86
19-309 - 2/9/88
19-558 - 12/29/87
19-778 - 2/16/89

APPROVABLE

GBuehler
6/9/95

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-046

Approved Labeling

NDA 18-998

S-046

AP 9/28/95



7825152

APPROVED
VASOTEC (Enalapril Maleate)

MERCK & CO., INC.
West Point, PA 19486, USA


TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, VASOTEC should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

DESCRIPTION

VASOTEC® (Enalapril Maleate) is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin converting enzyme inhibitor, enalaprilat. Enalapril maleate is chemically described as (S)-1-[N-(1-ethoxycarbonyl)-3-phenylpropyl]-L-proline, (2S,2'-butenedioate salt (1:1). Its empirical formula is $C_{27}H_{35}N_2O_7 \cdot C_4H_4O_6$, and its structural formula is:



Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol.

Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin converting enzyme inhibitor.

Enalapril maleate is supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for oral administration. In addition to the active ingredient enalapril maleate, each tablet contains the following inactive ingredients: lactose, magnesium stearate, starch, and other ingredients. The 2.5 mg, 10 mg and 20 mg tablets also contain iron oxides.

CLINICAL PHARMACOLOGY

Mechanism of Action

Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive patients treated with VASOTEC alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with VASOTEC plus a thiazide diuretic, there was essentially no change in serum potassium. (See PRECAUTIONS.) Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodilator peptide, play a role in the therapeutic effects of VASOTEC remains to be elucidated.

While the mechanism through which VASOTEC lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, VASOTEC is antihypertensive even in patients with low-renin hypertension. Although VASOTEC was antihypertensive in all races studied, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalapril monotherapy than non-black patients.

Pharmacokinetics and Metabolism

Following oral administration of VASOTEC, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of absorption of enalapril is approximately 80 percent. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract. Following absorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum concentrations of enalaprilat occur three to four hours after an oral dose of enalapril maleate. Excretion of VASOTEC is primarily renal. Approximately 84 percent of the dose is recovered in the urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about 40 percent of the dose, and intact enalapril. There is no evidence of metabolites of enalapril, other than enalaprilat.

Registered trademark of MERCK & CO., Inc.
COPYRIGHT © MERCK & CO., Inc., 1982, 1986, 1992, 1993
All rights reserved

The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours.

The disposition of enalapril and enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 20 mL/min or less. With glomerular filtration rate ≤ 30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at the level of renal insufficiency. (See DOSAGE AND ADMINISTRATION.) Enalaprilat is dialyzable at the rate of 62 mL/min.

Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of ^{14}C enalapril maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.

Pharmacodynamics and Clinical Effects

Hypertension: Administration of VASOTEC to patients with hypertension of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients. (See WARNINGS.)

In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours.

All recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval (see DOSAGE AND ADMINISTRATION).

In some patients achievement of optimal blood pressure reduction may require several weeks of therapy.

The antihypertensive effects of VASOTEC have continued during long term therapy. Abrupt withdrawal of VASOTEC has not been associated with a rapid increase in blood pressure.

In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of VASOTEC, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.

When given together with thiazide-type diuretics, the blood pressure lowering effects of VASOTEC are approximately additive.

In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC.

Heart Failure: In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure and heart size, and increased cardiac output and exercise tolerance. Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of heart failure as measured by the New York Heart Association (NYHA) classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose, and appeared to be maintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies lasting from eight weeks to over one year.

Heart Failure, Mortality Trials: In a multicenter, placebo-controlled clinical trial, 2,589 patients with all degrees of symptomatic heart failure and ejection fraction ≤ 35 percent were randomized to placebo or enalapril and followed for up to 66 months (SOLVD-Treatment). Use of enalapril was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for heart failure. Diseases that excluded patients from enrollment in the study included severe stable angina (>2 attacks/day), hemodynamically significant valvular or outflow tract obstruction, renal failure (creatinine >2.5 mg/dL), cerebral vascular disease (e.g., significant carotid artery disease), advanced pulmonary disease, malignancies, active myocarditis and congestive pericarditis. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present.

A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction ≤ 35 percent and no history of symptomatic heart failure, were randomized to placebo (n=2117) or enalapril (n=2111) and followed for up to 6 years. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 60 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32% fewer first hospitalizations for heart failure, and 32% fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiv-

VASOTEC® (Enalapril Maleate)

ing enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1168 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect.

The SOLVD-Prevention trial was not designed to determine whether treatment of asymptomatic patients with low ejection fraction would be superior, with respect to preventing hospitalization, to closer follow-up and use of enalapril at the earliest sign of heart failure. However, under the conditions of follow-up in the SOLVD-Prevention trial (every 4 months at the study clinic; personal physician as needed), 68% of patients on placebo who were hospitalized for heart failure had no prior symptoms recorded which would have signaled initiation of treatment.

The SOLVD-Prevention trial was also not designed to show whether enalapril modified the progression of underlying heart disease.

In another multicenter, placebo-controlled trial (CONSENSUS) limited to patients with NYHA Class IV congestive heart failure and radiographic evidence of cardiomegaly, use of enalapril was associated with improved survival. The results are shown in the following table.

	SURVIVAL (%)	
	Six Months	One Year
VASOTEC (n=127)	74	64
Placebo (n=126)	56	48

In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both.

INDICATIONS AND USAGE

Hypertension

VASOTEC is indicated for the treatment of hypertension. VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive.

Heart Failure

VASOTEC is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials).

Asymptomatic Left Ventricular Dysfunction

In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤ 35 percent), VASOTEC decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.)

In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk. (See WARNINGS.)

In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema.)

CONTRAINDICATIONS

VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor.

WARNINGS

Anaphylactoid and Possibly Related Reactions

Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of mucosaccharides and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including VASOTEC) may be subject to a variety of adverse reactions, some of them serious.

Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including VASOTEC. This may occur at any time during treatment. In such cases VASOTEC should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided. (See ADVERSE REACTIONS.)

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema

TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

Circular Number 7825152



TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

Circular Number 7825152



TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

Circular Number 7825152



TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

Circular Number 7825152



TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

Circular Number 7825152



TABLETS
VASOTEC®
(ENALAPRIL MALEATE)

Circular Number 7825152



10257b2
VASOTEC® (Enalapril Maleate)

while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS).

Anaphylactoid reactions during desensitization: Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenges.

Anaphylactoid reactions during membrane exposure: Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate adsorption (a procedure dependent upon devices not approved in the United States).

Hypotension

Excessive hypotension is rare in uncomplicated hypertensive patients treated with VASOTEC alone. Patients with heart failure given VASOTEC commonly have some reduction in blood pressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy. (See DOSAGE AND ADMINISTRATION.) Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic (except in patients with heart failure), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive hypotension who are able to tolerate such adjustments. (See PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS.) In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If excessive hypotension occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of VASOTEC, which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary.

Neutropenia/Agranulocytosis

Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Marking experience has revealed several cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

Hepatic Failure

Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

Fetal/Neonatal Morbidity and Mortality

ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.

The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.

These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of VASOTEC as soon as possible.

Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the poten-

VASOTEC® (Enalapril Maleate)

tial hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment.

If oligohydramnios is observed, VASOTEC should be discontinued unless it is considered lifesaving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

No teratogenic effects of enalapril were seen in studies of pregnant rats, and rabbits. On a mg/kg basis, the doses used were up to 333 times (in rats), and 50 times (in rabbits) the maximum recommended human dose.

PRECAUTIONS

General

Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including VASOTEC, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.

Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when VASOTEC has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dose reduction and/or discontinuation of the diuretic and/or VASOTEC may be required.

Evaluation of patients with hypertension or heart failure should always include assessment of renal function. (See DOSAGE AND ADMINISTRATION.)

Hypertalemia: Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. Hypertalemia was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. In clinical trials in heart failure, hypertalemia was observed in 3.8 percent of patients but was not a cause for discontinuation.

Risk factors for the development of hypertalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with VASOTEC. (See Drug Interactions.)

Cough: Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.

Surgery/Anesthesia: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Information for Patients

Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

Hypotension: Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

Hypertalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.



VASOTEC® (Enalapril Maleate)

Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions

Hypotension - Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION.)

Agents Causing Renin Release: The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).

Other Cardiovascular Agents: VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.

Agents Increasing Serum Potassium: VASOTEC attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium sparing agents should generally not be used in patients with heart failure receiving VASOTEC.

Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of a tumorigenic effect when enalapril was administered for 104 weeks to rats at doses up to 90 mg/kg/day (150 times* the maximum daily human dose). Enalapril has also been administered for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively, (150 and 300 times* the maximum daily dose for humans) and showed no evidence of carcinogenicity.

Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rat-spleen reverse mutation assay with *E. coli*, sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an *in vivo* cytogenetic study using mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with 10 to 90 mg/kg/day of enalapril.

Pregnancy Categories C (first trimester) and D (second and third trimesters). See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Nursing Mothers

Enalapril and enalaprilat are detected in human milk in trace amounts. Caution should be exercised when VASOTEC is given to nursing mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

VASOTEC has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2967 patients.

For the most part, adverse experiences were mild and transient in nature. In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with hypertension the overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo.

HYPERTENSION

Adverse experiences occurring in greater than one percent of patients with hypertension treated with VASOTEC in con-

*Based on patient weight of 60 kg

7825152

VASOTEC® (Enalapril Maleate)

rolled clinical trials are shown below. In patients treated with VASOTEC, the maximum duration of therapy was three years; in placebo treated patients the maximum duration of therapy was 12 weeks.

	VASOTEC (n = 2314) Incidence (discontinuation)	Placebo (n = 2300) Incidence
Body As A Whole		
Fatigue	3.0 (<0.1)	2.8
Orthostatic Effects	1.2 (<0.1)	0.0
Asthenia	1.1 (0.1)	0.0
Digestive		
Diarrhea	1.4 (<0.1)	1.7
Nausea	1.4 (0.2)	1.7
Nervous/Psychiatric		
Headache	5.2 (0.3)	6.1
Dizziness	4.3 (0.4)	4.3
Respiratory		
Cough	1.3 (0.1)	0.9
Skin		
Rash	1.4 (0.4)	0.4

HEART FAILURE

Adverse experiences occurring in greater than one percent of patients with heart failure treated with VASOTEC are shown below. The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year). In the placebo treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks). The percentage of patients with severe heart failure (NYHA Class IV) was 29 percent and 43 percent for patients treated with VASOTEC and placebo, respectively.

	VASOTEC (n = 573) Incidence (discontinuation)	Placebo (n = 338) Incidence
Body As A Whole		
Orthostatic Effects	2.2 (0.1)	0.3
Syncope	2.2 (0.1)	0.9
Chest Pain	2.1 (0.0)	2.1
Fatigue	1.9 (0.0)	1.6
Abdominal Pain	1.6 (0.4)	2.1
Asthenia	1.6 (0.1)	0.3
Cardiovascular		
Hypotension	6.7 (1.9)	0.6
Orthostatic Hypotension	1.6 (0.1)	0.3
Angina Pectoris	1.5 (0.1)	1.6
Myocardial Infarction	1.2 (0.3)	1.6
Digestive		
Diarrhea	2.1 (0.1)	1.2
Nausea	1.3 (0.1)	0.6
Vomiting	1.3 (0.0)	0.9
Nervous/Psychiatric		
Dizziness	7.9 (0.6)	0.6
Headache	1.6 (0.1)	0.9
Vertigo	1.6 (0.1)	1.2
Respiratory		
Cough	2.2 (0.0)	0.6
Bronchitis	1.3 (0.0)	0.9
Dyspnea	1.3 (0.1)	0.4
Pneumonia	1.0 (0.0)	2.4
Skin		
Rash	1.3 (0.0)	2.4
Urogenital		
Urinary Tract Infection	1.3 (0.0)	2.4

Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in 0.5 to 1.0 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity.

Body As A Whole: Anaphylactoid reactions (see WARNINGS, Anaphylactoid and Possibly Related Reactions).

Cardiovascular: Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension); pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation.

Digestive: Ileus, pancreatitis, hepatic failure, hepatitis (hepatocellular [proven on rechallenge] or cholestatic [anecdotal] (see WARNINGS, Hepatic Failure), melena, anorexia, dyspepsia, constipation, glossitis, stomatitis, dry mouth.

Hematologic: Rare cases of neutropenia, thrombocytopenia and bone marrow depression.

Musculoskeletal: Muscle cramps.

Nervous/Psychiatric: Depression, confusion, ataxia, somnolence, incontinence, nervousness, peripheral neuropathy (e.g., paresthesia, dysesthesia).

Respiratory: Bronchospasm, rhinorrhea, sore throat and hoarseness, edema, upper respiratory infection, pulmonary infiltrates.

Skin: Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, herpes zoster.

VASOTEC® (Enalapril Maleate)

erythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity.

Special Senses: Blurred vision, taste alteration, anosmia, tinnitus, conjunctivitis, dry eyes, tearing.

Urogenital: Renal failure, oliguria, renal dysfunction (see PRECAUTIONS and DOSAGE AND ADMINISTRATION), flank pain, gynecomasia, impotence.

Miscellaneous: A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations.

Angioedema: Angioedema has been reported in patients receiving VASOTEC, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, pharynx and/or larynx occurs, treatment with VASOTEC should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.)

Hypotension: In the hypertensive patients, hypotension occurred in 0.9 percent and syncope occurred in 0.5 percent of patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for discontinuation of therapy in 0.1 percent of hypertensive patients. In heart failure patients, hypotension occurred in 6.7 percent and syncope occurred in 2.2 percent of patients. Hypotension or syncope was a cause for discontinuation of therapy in 1.9 percent of patients with heart failure. (See WARNINGS.)

Fetal/Neonatal Morbidity and Mortality: See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Cough: See PRECAUTIONS, Cough.

Clinical Laboratory Test Findings

Serum Electrolytes: Hyperkalemia (see PRECAUTIONS), hyponatremia.

Creatinine, Blood Urea Nitrogen: In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2 percent of patients with essential hypertension treated with VASOTEC alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis. (See PRECAUTIONS.) In patients with heart failure who were also receiving diuretics with or without digitals, increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of VASOTEC and/or other concomitant diuretic therapy, were observed in about 11 percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in 1.2 percent of patients.

Hematology: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in either hypertension or congestive heart failure patients treated with VASOTEC but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to anemia. Hemolytic anemia, including cases of hemolysis in patients with G-6-PD deficiency, has been reported; a causal relationship to enalapril cannot be excluded.

Liver Function Tests: Elevations of liver enzymes and/or serum bilirubin have occurred (see WARNINGS, Hepatic Failure).

OVERDOSAGE

Limited data are available in regard to overdosage in humans.

The oral LD₅₀ of enalapril is 2000 mg/kg in mice and rats.

The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Enalapril may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis.

DOSAGE AND ADMINISTRATION

Hypertension

In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of VASOTEC. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension. (See WARNINGS.) If the patient's blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed.

If the diuretic cannot be discontinued an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.)

The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, an increase in dosage or twice daily administration should be considered. If blood pressure is not controlled with VASOTEC alone, a diuretic may be added.

Concomitant administration of VASOTEC with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see PRECAUTIONS).

Dosage Adjustment in Hypertensive Patients with Renal

7826152
VASOTEC® (Enalapril Maleate)

Impairment

The usual dose of enalapril is recommended for patients with a creatinine clearance >30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance <30 mL/min (serum creatinine ≥3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

Renal Status	Creatinine Clearance mL/min	Initial Dose mg/day
Normal Renal Function	>80 mL/min	5 mg
Mild Impairment	≥80 <30 mL/min	5 mg
Moderate to Severe Impairment	<30 mL/min	2.5 mg
Dialysis Patients***		2.5 mg on dialysis days*

***See WARNINGS, Anaphylactoid reactions during membrane exposures

*Dosage on nondialysis days should be adjusted depending on the blood pressure response.

Heart Failure

VASOTEC is indicated for the treatment of symptomatic heart failure, usually in combination with diuretics and digitalis. In the placebo-controlled studies that demonstrated improved survival, patients were titrated as tolerated up to 40 mg, administered in two divided doses.

The recommended initial dose is 2.5 mg. The recommended dosing range is 2.5 to 20 mg given twice a day. Doses should be titrated upward, as tolerated, over a period of a few days or weeks. The maximum daily dose administered in clinical trials was 40 mg in divided doses.

After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.) If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension.

Asymptomatic Left Ventricular Dysfunction

In the trial that demonstrated efficacy, patients were started on 2.5 mg twice daily and were titrated as tolerated to the targeted daily dose of 20 mg (in divided doses).

After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.) If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension.

Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hypotension

In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision. (See DOSAGE AND ADMINISTRATION, Heart Failure, WARNINGS and PRECAUTIONS, Drug Interactions.) The dose may be increased to 2.5 mg b.i.d., then 5 mg b.i.d. and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there is not excessive hypotension or significant deterioration of renal function. The maximum daily dose is 40 mg.

HOW SUPPLIED

No. 3411 - Tablets VASOTEC, 2.5 mg, are yellow, biconvex barrel shaped, scored, compressed tablets with code MSD 14 on one side and VASOTEC on the other. They are supplied as follows:

NDC 0006-0014-84 unit of use bottles of 90 (with desiccant)
NDC 0006-0014-68 bottles of 100 (with desiccant)
(6506-01-361-3157, 2.5 mg 100's)
NDC 0006-0014-28 unit dose packages of 100
NDC 0006-0014-98 unit of use bottles of 100 (with desiccant)
NDC 0006-0014-82 bottles of 1,000 (with desiccant)

No. 3412 - Tablets VASOTEC, 5 mg, are white, barrel shaped, scored, compressed tablets with code MSD 712 on one side and VASOTEC on the other. They are supplied as follows:

NDC 0006-0712-94 unit of use bottles of 90 (with desiccant)
NDC 0006-0712-68 bottles of 100 (with desiccant)
(8506-01-238-8883, 5 mg 100's)
NDC 0006-0712-28 unit dose packages of 100
(8506-01-244-4811, 5 mg individually sealed 100's)
NDC 0006-0712-98 unit of use bottles of 100 (with desiccant)
NDC 0006-0712-82 bottles of 1,000 (with desiccant)
NDC 0006-0712-81 bottles of 4,000 (with desiccant)
(8506-01-319-8626, 5 mg 4,000's)
NDC 0006-0712-87 bottles of 10,000 (with desiccant)
(8506-01-378-5676, 5 mg 10,000's)

No. 3413 - Tablets VASOTEC, 10 mg, are salmon, barrel shaped, compressed tablets, with code MSD 713 on one side and VASOTEC on the other. They are supplied as follows:
NDC 0006-0713-84 unit of use bottles of 90 (with desiccant)

VASOTEC® (Enalapril Maleate)

NDC 0006-0713-68 bottles of 100 (with desiccant)
(8506-01-238-8881, 10 mg 100's)
NDC 0006-0713-28 unit dose packages of 100
(6506-01-314-6028, 10 mg individually sealed 100's)
NDC 0006-0713-98 unit of use bottles of 100 (with desiccant)
NDC 0006-0713-82 bottles of 1,000 (with desiccant)
NDC 0006-0713-81 bottles of 4,000 (with desiccant)
(8506-01-320-4728, 10 mg 4,000's)
NDC 0006-0713-87 bottles of 10,000 (with desiccant)
(8506-01-378-8022, 10 mg 10,000's)
No. 3414 - Tablets VASOTEC, 20 mg, are peach, barrel shaped, compressed tablets, with code MSD 714 on one side and VASOTEC on the other. They are supplied as follows:
NDC 0006-0714-94 unit of use bottles of 90 (with desiccant)
NDC 0006-0714-68 bottles of 100 (with desiccant)
(8506-01-227-0545, 20 mg 100's)
NDC 0006-0714-28 unit dose packages of 100
(8506-01-318-0465, 20 mg individually sealed 100's)
NDC 0006-0714-82 bottles of 1,000 (with desiccant)
NDC 0006-0714-87 bottles of 10,000 (with desiccant)
(8506-01-378-8780, 20 mg 10,000's)

Storage

Store below 30°C (86°F) and avoid transient temperatures above 50°C (122°F). Keep container tightly closed. Protect from moisture.

Dispense in a light container, if product package is subdivided.

MERCK & CO., INC., West Point, PA 19386, USA

Issued July 1995
Printed in USA

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-046

Administrative/Correspondence

CSO Review of Labeling

SEP 28 1995

NDA: 18-998/S-046 Vasotec (enalapril maleate) Tablets
19-221/S-021 Vaseretic (enalapril maleate/HCTZ) Tablets
19-309/S-019 Vasotec (enalaprilat) I.V.
19-558/S-031 Prinivil (lisinopril) Tablets
19-778/S-025 Prinzide (lisinopril/HCTZ) Tablets

Date of submissions: August 24, 1995

Date of receipt: August 25, 1995

Applicant: Merck Research Laboratories

Background: On January 27, 1995, we issued a Supplement Request Letter to all approved ACE inhibitors, asking that the package inserts be changed to add language to the INDICATIONS AND USAGE section similar to the following:

In considering use of Tradename, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

Merck responded with supplements dated May 10, 1995, that proposed making revisions to the WARNINGS and ADVERSE REACTIONS sections of the labeling. We issued an approvable letter dated June 19, 1995, that stated that Merck should make the change in the INDICATIONS AND USAGE section as originally requested; however, they could use the revised wording that they had proposed. We also allowed the use of a new subheading _____ for the ADVERSE REACTIONS section. We also asked the firm to remove the word _____ from the WARNINGS and ADVERSE REACTIONS sections of the labeling.

Review: These supplements provide for final printed labeling revised as follows:

INDICATIONS AND USAGE:

NDA 18-998, 19-309, 19-558

In considering use of Vasotec/Vasotec I.V./Prinivil, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema.)

NDA 19-221 and 19-778

In considering use of Vaseretic/Prinzide, _____

(See WARNINGS, Angioedema.)

WARNINGS, Anaphylactoid and Possibly Related Reactions, Angioedema: a reference to the _____ section has been added.

ADVERSE REACTIONS, Angioedema: The phrase "with an incidence higher in black than in non-black patients" has been added to the first sentence of this subsection. The word _____ was deleted from this sentence in the Prinzide labeling.

It is not clear why the sentences _____
_____ and _____

_____ under INDICATIONS AND USAGE specify ACE inhibitor monotherapy, since angioedema was seen in patients on ACE inhibitor/HCTZ combination products. In his memo dated December 9, 1994, Dr. Norman Stockbridge notes that for benazepril, 7 subjects (4 caucasian, 2 black, 1 other) developed angioedema on benazepril/HCTZ, and in this database black patients comprised 15% of the subjects. There is no mention of the rates of angioedema seen with other combination products.

I suggest that we ask the firm to delete the word "monotherapy" from these sentences at the time of the next printing and add an "s" to "ACE inhibitor," _____

_____ and "In considering use of Vaseretic/Prinzide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks."

Recommendation: I will prepare an approval letter for these supplements.

Kathleen F. Bongiovanni 9-11-95
Kathleen F. Bongiovanni

- cc: 18-998/S-046
- 19-221/S-021
- 19-309/S-019
- 19-558/S-031
- 19-778/S-025
- HFD-110 (all)
- HFD-111/KBongiovanni
- HFD-111/SBenton

kb/9/8/95.